Personalis
1330 O’Brien Drive
Menlo Park
California
94025
United States
Tel: 1-650-752-1300
Website: http://www.personalis.com/
215 articles about Personalis
-
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
3/31/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.
-
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
3/24/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Personalis’ new Board Chair effective as of Personalis’ Annual Meeting of Stockholders on May 17, 2022.
-
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
3/23/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held in-person and online, April 8-13, 2022.
-
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
2/24/2022
Personalis, Inc., a leader in advanced genomics for precision oncology, reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
2/15/2022
Personalis, Inc. today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies.
-
Personalis to Announce Fourth Quarter and Full-Year 2021 Financial Results
2/10/2022
Personalis, Inc., a leader in advanced genomics for cancer, announced that it will release its fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022.
-
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/1/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time.
-
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
1/6/2022
Personalis, Inc., a leader in advanced genomics for cancer and population sequencing, reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021.
-
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
12/28/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022.
-
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
12/16/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed with cancer.
-
Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
11/18/2021
Personalis, Inc. (Nasdaq: PSNL), announced today that its management will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021.
-
Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
11/11/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium.
-
Personalis Reports Third Quarter 2021 Financial Results
11/4/2021
Personalis, Inc., a leader in advanced genomics for cancer and population sequencing, reported financial results for the third quarter ended September 30, 2021.
-
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
11/2/2021
Personalis, Inc., a leader in advanced genomics for cancer, announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy.
-
Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform
10/26/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy™.
-
Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
10/26/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the publication of its study “Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation,” in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics.
-
Personalis to Announce Third Quarter Financial Results on November 4, 2021
10/21/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021.
-
Personalis Expands Leadership Team With Appointment of Robert Bruce, Vice President of Reimbursement
10/13/2021
Personalis, Inc., a leader in advanced genomics for cancer, announced the appointment of Robert Bruce to the newly created position of Vice President of Reimbursement.
-
Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth
9/19/2021
Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced that the U.S. Department of Veterans Affairs Million Veteran Program has issued a new task order under its current contract with the company, with a value of up to approximately $10 million.
-
Personalis to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
8/26/2021
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time.